Groupe Athena,
Inc. (Pink sheets GATA.PK) announced today that it is one of 3 companies
nominated for the prestigious CFI.CO award for best pharmaceutical consultancy
company from
CFI.co, a print journal and online resource,
headquartered in
Reacting to the nomination, the Company’s Chairman, D. Purohit stated, “We are honored and humbled by this prestigious nomination and will continue to work towards maximizing shareholder value whilst ensuring customer satisfaction”.
About Groupe Athena, Inc.
Groupe Athena, Inc.
was incorporated in June 2008 and
began operations on July 1 of
that year. The company is a research and testing organization and helps various
pharmaceutical and medical products and devices companies in
The company has a research and
marketing facility in
For more information
contact:
Groupe Athena, Inc.
Certain statements set
forth in this press release constitute "forward-looking statements.”
Forward-looking statements include, without limitation, any statement that may
predict, forecast, indicate, or imply future results, performance or achievements,
and may contain the words "estimate", "project",
"intend", "forecast", "anticipate",
"plan", "planning", "expect",
"believe", "will likely", "should",
"could", "would", "may" or words or expressions
of similar meaning. Such statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause the company's
actual results and financial position to differ materially from those included
within the forward-looking statements. Forward-looking statements involve risks
and uncertainties, including those relating to the Company's ability to grow
its business. Actual results may differ materially from the results predicted
and reported results should not be considered as an indication of future
performance. The potential risks and uncertainties include, among others, the
Company's limited operating history, the limited financial resources, domestic
or global economic conditions -- activities of competitors and the presence of
new or additional competition and conditions of equity markets.